J Dermatolog Treat. 2025 Dec;36(1):2558995. doi: 10.1080/09546634.2025.2558995. Epub 2025 Sep 10.
ABSTRACT
BACKGROUND: Ivarmacitinib (SHR0302), a selective Janus kinase-1 inhibitor, is a novel treatment for moderate-to-severe atopic dermatitis (AD).
OBJECTIVES: This post hoc analysis evaluated the impact of early itch relief with ivarmacitinib on quality of life (QoL), working productivity, and sleep quality in affected patients.
METHODS: Data from ivarmacitinib treatment groups in a phase III trial (NCT04875169) were analyzed. Patients were classified as early itch responders (EIR; ≥4-point reduction in Worst Itch Numeric Rating Scale at week 4) or non-early itch responders (non-EIR). Outcomes included the Dermatology Life Quality Index (DLQI) total score, DLQI 0/1 response rate, DLQI work/study item, and the Patient-Oriented Eczema Measure (POEM) sleep item.
RESULTS: Of 225 patients, 90 were EIR and 135 were non-EIR. The EIR group showed significantly greater improvements in DLQI total score, DLQI 0/1 response rate, and work productivity from week 4 through week 52 compared to the non-EIR group. Sleep disturbance due to itch was also significantly improved in the EIR group from week 4 to week 40, though the difference at week 52 was not statistically significant.
CONCLUSIONS: Early itch relief with ivarmacitinib showed significant improvements in QoL, sleep, and work productivity in patients with moderate-to-severe AD.
PMID:40931395 | DOI:10.1080/09546634.2025.2558995
